Revenue

CentFX won a top broker award but faces scrutiny as it launches a payment card and crypto token. Can it build a trusted fintech ecosystem or will it buckle?

Nuveen Churchill Direct Lending Corp. adjusts its shareholder return strategy in response to a changing interest rate and spread environment.

On the war's fourth anniversary, Kyivstar's board, including Mike Pompeo, visited Kyiv, reaffirming a $1B investment and honoring resilient employees.

As Matricelf presents its breakthrough therapy at a major summit, the company moves closer to human trials, offering new hope for paralysis patients.

The burger chain posted robust revenue and a massive jump in annual net income, outperforming rivals and detailing plans for major global expansion.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Former USAA CEO Wayne Peacock joins Cotality's board, signaling a strategic push to lead the AI-driven property data and insurance analytics market.

Consolidated Lithium Metals aims to raise $17.07 million to advance its Quebec rare earth and lithium projects, capitalizing on key investor tax incentives.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

Facing slow auto OEM cycles, Arbe Robotics names a new CEO and targets defense, robotaxis, and China to accelerate revenue from its high-res radar tech.

In a market dominated by wood, one developer is betting on steel. Discover how cold-formed steel is creating stronger, safer, and more resilient homes.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

The energy giant unveils a massive capital plan to boost regulated assets, even as a $471M write-down on renewables reveals significant grid challenges.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

Middleby names veteran leaders for its high-growth Food Processing unit, setting the stage for a 2026 public debut in a booming automation market.

Kolibri Global Energy Inc. just released its first sustainability report. Is it a genuine shift or a strategic play in a world demanding greener energy?